KODIAK SCIENCES INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
KODIAK SCIENCES INC. (KOD) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$154.53 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-31
- KODIAK SCIENCES INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$154.53M.
- KODIAK SCIENCES INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$118.78M.
- KODIAK SCIENCES INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$143.26M.
- KODIAK SCIENCES INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$163.24M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$154.53M 10-K · filed 2026-03-31 |
| 2024-12-31 | -$118.78M 10-K · filed 2026-03-31 |
| 2023-12-31 | -$143.26M 10-K · filed 2026-03-31 |
| 2022-12-31 | -$163.24M 10-K · filed 2025-03-27 |
| 2021-12-31 | -$46.59M 10-K · filed 2024-03-28 |
| 2020-12-31 | -$17.27M 10-K · filed 2023-03-28 |
| 2019-12-31 | $2.63M 10-K · filed 2022-03-01 |
| 2018-12-31 | -$17.27M 10-K · filed 2021-03-01 |
| 2017-12-31 | -$3.24M 10-K · filed 2020-03-16 |
| 2016-12-31 | -$14.63M 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |